Redeye Members Network

To access members-only content, you must login or register an account. The Redeye membership is free, but you need to apply via our application form.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

  • Peers

Catalyst Potential

It is important to look beyond the numbers and seek a likely catalysts, which could unlock value, and estimate how long it will take for the catalyst to play out. These events, or Catalyst Potential, reduce risk by narrowing the gap between price and value in a more predictable way. This is particularly important when investing in a low-quality business where time is like a ticking bomb stacked against the company.

Catalyst Potential is a Premium members feature in Redeye Universe.

APPLY FOR MEMBERSHIP

Redeye Rating

Mathias Spinnars

Equity Analyst

mathias.spinnars@redeye.se

+46854501330

Company Quality

  • 6.0
  • 4.0
  • 4.0
  • 0.0
  • 0.0

Leadership

Exclusive for members
Bolaget har en begränsad organisation med relevant erfarenhet från branschen. Ersättningsnivåer och incitamentsprogram för ledande befattningshavare framstår vara väl avvägda. Kommunikationen med marknaden har ökat i aktivitet, vilket är ett bra steg.

Ownership

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profit outlook

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profitability

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Capital Strength

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bear Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bull Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Base Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Latest price

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Fair Value Range

Last Price
Key Model Assumptions - The Bear Case
Key Model Assumptions - The Bull Case
Key Model Assumptions - The Base Case

Catalyst Potential

Impact

Timeframe

Short
Mid
Long

Company description

Hansa Medical utvecklar innovativa enzymbaserade läkemedel för att möjliggöra njurtransplantation för fler behövande, samt för behandling av ovanliga autoimmuna sjukdomar. IdeS är i klinisk utvecklingsfas och marknaden uppskattas till drygt 1 miljard kronor per år i EU och USA. Bolaget har även utvecklat och licensierat ut en diagnostikmetod (HBP-analys) för prediktion av svår blodförgiftning vid akutkliniker. Read more...
Hansa Medical utvecklar innovativa enzymbaserade läkemedel för att möjliggöra njurtransplantation för fler behövande, samt för behandling av ovanliga autoimmuna sjukdomar. IdeS är i klinisk utvecklingsfas och marknaden uppskattas till drygt 1 miljard kronor per år i EU och USA. Bolaget har även utvecklat och licensierat ut en diagnostikmetod (HBP-analys) för prediktion av svår blodförgiftning vid akutkliniker. Metoden möjliggör snabbare omhändertagande vilket kan rädda liv och sänka vårdkostnader. Samarbetspartnern Axis-Shield Diagnostic har marknadslanserat metoden och Hansa Medical har rätt till royalties. Less...

TODAY

Day High
107.25
106.50
0.75
-0.7%
Day Low
105.00
Day Open
107.00
Prev Close
106.50
VWAP
106.2
Volume
86K
Turnover
9.100M
Top Broker
VWAP
106.5
Avg Volume
99K
Avg Turnover
10.536M
Top Brokers
AVA/NON

52 WEEK SUMMARY

Price Range
Beta
n/a
Market Cap
3,733.3M
Total Return
324.3%
Trailing P/E
-52.1
Div Yield
0.0%
Shares Outstanding
35.1M
Next Earnings Date
26 Apr
Stock Exchange
NASDAQ Stockholm

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Rel Price Chg 3 Months -12.6%
Rel Price Chg 12 Months 270.5%
Volume Trend
Avg Vol 10 vs 60 Days 29.3%
Price vs...
52-Week High -29.9%
50-Day Moving Average -6.0%
200-Day Moving Average 9.6%

Historic pricing of Hansa Medical

Last price: 106.50 SEK

Loading data...

Prev Close [[ prevClose|number:2 ]] SEK Change [[ changeValue|number:2 ]] %
High [[ highValue|number:2 ]] SEK Avg Daily Volume [[ avgVolume|number:0 ]] Shares
Low [[ lowValue|number:2 ]] SEK Avg Daily Turnover [[ graphAvgTurnover|number:2 ]] SEK

Management

Göran Arvidson, CEO
Eva-Maria Joed, CFO

Executive Board

Ulf Wiinberg, Chairman of the board
Stina Gestrelius
Hans Schikan

Last updated: 2016-11-08 Source: Redeye

Major Holders

Owner Equity Votes
Nexttobe 29.1%
2.1%
Gladiator Fonder 7.8%
7.8%
Avanza Pension 3.7%
3.7%
AFA Försäkring 2.5%
2.5%
Tredje AP-fonden 1.7%
1.7%
Sven Sandberg 1.6%
1.6%

Last updated: 2016-11-08 Source: Redeye

Insider transaction summary

Total insider purchases and sales reported

Timeframe Transactions Net Shares
Last 12 Weeks

0 Purchases

+ 0

0 Sales

- 0

Last 24 Weeks

0 Purchases

+ 0

0 Sales

- 0

Most recent insider transactions

Exclusive for members
Report Date Name Position Transaction Shares Chg Est Value (SEK)
2015-12-15 Kvist, Sture ANB Sale + 65 66
2015-12-15 Kvist, Malin ANB Sale + 48 163
2015-12-15 Kvist, Sture ANB Sale + 13 125
2015-12-15 Kvist, Sture ANB Sale + 59 23
2015-12-15 Kvist, Malin ANB Sale + 73 163

Source: Millistream – FI

More
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt (SEKm)
  • Capital employed (SEKm)
  • Capital turnover rate
Previous year Next year
2014
  • -61.0%
  • -51.5%
  • -53.8%
  • -1,610.5%
  • -1,527.1%
  • -1,794.9%
  • -1.12
  • -1.12
  • 0.00
  • -0.39
  • 25.9M
  • 2,751.5
  • -95.1
  • -95.1
  • 1,706.7
  • 1,700.5
  • -105.6
  • -111.4
  • 55.4
  • 91.7%
  • 0.0%
  • -10
  • 40
  • 0.0
2015
  • -50.7%
  • -50.6%
  • -166.4%
  • -1,233.9%
  • -1,218.3%
  • -1,219.5%
  • -2.04
  • -2.04
  • 0.00
  • -5.42
  • 32.4M
  • 3,276.3
  • -52.1
  • -52.1
  • 635.2
  • 602.9
  • -48.9
  • -49.5
  • 16.3
  • 94.4%
  • 0.0%
  • -176
  • 36
  • 0.0
2016E
  • -63.1%
  • -63.3%
  • -283.1%
  • -3,015.6%
  • -2,990.6%
  • -2,981.8%
  • -3.13
  • -3.13
  • 0.00
  • -3.00
  • 32.4M
  • 3,354.5
  • -34.0
  • -34.0
  • 1,010.7
  • 986.0
  • -32.7
  • -33.0
  • 31.2
  • 95.7%
  • 0.0%
  • -97
  • 13
  • 0.0
2017E
  • -175.0%
  • -143.7%
  • -810.0%
  • -1,380.6%
  • -1,369.3%
  • -1,366.6%
  • -3.17
  • -3.17
  • 0.00
  • 0.36
  • 32.4M
  • 3,463.6
  • -33.6
  • -33.6
  • 495.5
  • 460.7
  • -33.4
  • -33.6
  • 507.6
  • 18.3%
  • 0.7%
  • 12
  • 19
  • 0.2
2018E
  • 0.0%
  • -342.2%
  • -492.7%
  • -217.4%
  • -215.4%
  • -215.4%
  • -2.90
  • -2.90
  • 0.00
  • 3.35
  • 32.4M
  • 3,560.3
  • -36.7
  • -36.7
  • 85.5
  • 81.6
  • -37.5
  • -37.9
  • -43.1
  • -273.1%
  • 3.1%
  • 108
  • 22
  • 1.4
2019E
  • 0.0%
  • 89.2%
  • 158.7%
  • 17.4%
  • 17.8%
  • 17.8%
  • 1.06
  • 1.06
  • 0.00
  • 3.33
  • 32.4M
  • 3,559.7
  • 100.0
  • 100.0
  • 19.3
  • 18.4
  • 105.7
  • 103.1
  • -71.5
  • -79.5%
  • 3.0%
  • 108
  • 56
  • 2.9
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
Previous year Next year
2014
  • 2
  • -28
  • -26
  • 1
  • 0
  • 0
  • -25
  • 0
  • -4
  • 0
  • -29
  • 0
  • -29
2015
  • 5
  • -72
  • -67
  • 1
  • 0
  • 0
  • -66
  • 0
  • -0
  • 0
  • -66
  • 0
  • -66
2016E
  • 8
  • 4
  • 3
  • 7
  • 4
  • 8
  • 0
  • 1
  • 0
  • 6
  • 5
  • 4
  • 7
Q1
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
Q2
  • 0
  • -0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
Q3E
  • 10
  • 8
  • 4
  • 6
  • 1
  • 10
  • 9
  • 4
  • 0
  • 4
  • 8
  • 7
  • 3
Q4E
  • 8
  • 10
  • 4
  • 7
  • 10
  • 5
  • 2
  • 9
  • 9
  • 4
  • 5
  • 3
  • 5
2016E
  • 10
  • 0
  • 10
  • 3
  • 4
  • 2
  • 9
  • 4
  • 1
  • 10
  • 1
  • 5
  • 10
2017E
  • 2
  • 0
  • 0
  • 5
  • 6
  • 6
  • 2
  • 2
  • 6
  • 7
  • 5
  • 0
  • 10
Q1E
  • 8
  • 5
  • 6
  • 4
  • 3
  • 8
  • 1
  • 0
  • 10
  • 7
  • 7
  • 4
  • 6
Q2E
  • 3
  • 2
  • 1
  • 10
  • 2
  • 1
  • 6
  • 1
  • 3
  • 8
  • 5
  • 9
  • 9
Q3E
  • 0
  • 2
  • 6
  • 5
  • 3
  • 8
  • 6
  • 2
  • 2
  • 4
  • 6
  • 2
  • 10
Q4E
  • 10
  • 6
  • 3
  • 2
  • 4
  • 4
  • 1
  • 1
  • 9
  • 0
  • 8
  • 0
  • 8
2017E
  • 7
  • 7
  • 2
  • 5
  • 6
  • 3
  • 4
  • 0
  • 10
  • 9
  • 4
  • 7
  • 10
2018E
  • 5
  • 6
  • 6
  • 1
  • 10
  • 0
  • 9
  • 10
  • 6
  • 4
  • 4
  • 9
  • 6
2019E
  • 0
  • 1
  • 10
  • 3
  • 8
  • 5
  • 9
  • 6
  • 0
  • 5
  • 5
  • 10
  • 1
Previous year Next year
    (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
Previous year Next year
2014
  • 10
  • 0
  • 0
  • 1
  • 12
  • 1
  • 0
  • 4
  • 0
  • 0
  • 37
  • 0
  • 42
  • 0
  • 54
  • 0
  • 2
  • 3
  • 4
  • 0
  • 0
  • 0
  • 5
  • 0
  • 0
  • 50
  • 0
  • 50
  • 54
2015
  • 176
  • 1
  • 0
  • 2
  • 178
  • 2
  • 0
  • 7
  • 0
  • 0
  • 36
  • 0
  • 46
  • 0
  • 224
  • 0
  • 1
  • 11
  • 13
  • 0
  • 0
  • 0
  • 13
  • 0
  • 0
  • 212
  • 0
  • 212
  • 224
2016E
  • 4
  • 5
  • 8
  • 10
  • 4
  • 0
  • 8
  • 9
  • 0
  • 10
  • 6
  • 9
  • 2
  • 0
  • 3
  • 5
  • 4
  • 5
  • 1
  • 4
  • 4
  • 9
  • 2
  • 0
  • 3
  • 2
  • 2
  • 4
  • 4
2017E
  • 7
  • 6
  • 10
  • 1
  • 6
  • 4
  • 6
  • 2
  • 2
  • 5
  • 3
  • 4
  • 9
  • 7
  • 10
  • 0
  • 8
  • 1
  • 5
  • 1
  • 0
  • 10
  • 6
  • 8
  • 10
  • 8
  • 10
  • 7
  • 6
2018E
  • 6
  • 2
  • 2
  • 10
  • 0
  • 3
  • 7
  • 6
  • 10
  • 8
  • 3
  • 2
  • 9
  • 5
  • 4
  • 7
  • 0
  • 6
  • 3
  • 2
  • 5
  • 0
  • 9
  • 3
  • 0
  • 0
  • 0
  • 9
  • 6
2019E
  • 3
  • 8
  • 3
  • 8
  • 3
  • 9
  • 8
  • 10
  • 0
  • 9
  • 6
  • 9
  • 5
  • 1
  • 5
  • 8
  • 6
  • 0
  • 9
  • 10
  • 8
  • 5
  • 10
  • 4
  • 6
  • 9
  • 8
  • 10
  • 6
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
Previous year Next year
2014
  • 2
  • -28
  • 1
  • -25
  • 0
  • -25
  • -1
  • -26
  • -0
  • 8
  • -19
2015
  • 5
  • -72
  • 1
  • -66
  • 0
  • -66
  • -1
  • -67
  • 7
  • -3
  • -62
2016E
  • 7
  • 9
  • 8
  • 6
  • 10
  • 8
  • 10
  • 2
  • 10
  • 0
  • 10
2017E
  • 7
  • 7
  • 0
  • 2
  • 1
  • 9
  • 10
  • 3
  • 3
  • 3
  • 7
2018E
  • 0
  • 1
  • 7
  • 8
  • 0
  • 2
  • 8
  • 7
  • 4
  • 7
  • 3
2019E
  • 8
  • 0
  • 2
  • 10
  • 9
  • 1
  • 6
  • 3
  • 5
  • 8
  • 5
Previous year Next year
More